Related Experiment Video
Updated: Jul 9, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Recent developments in cell-based immune therapy for neuroblastoma
Michael R Verneris1, John E Wagner
1Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Mayo Mail Code 366, 420 Delaware Street, S.E., Minneapolis, MN 55455, USA. verneris@umn.edu
Abstract:
Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, gammadelta T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.
Insights
Neuroblastoma (NB), a childhood cancer, has poor outcomes with standard treatments. Cellular immunotherapies like natural killer cells and T cells show promise for advanced or recurrent NB.
Area of Science:
- Pediatric Oncology
- Immunotherapy
- Cancer Research
Background:
- Neuroblastoma (NB) is a prevalent and aggressive pediatric cancer.
- Conventional treatments (chemotherapy, surgery, radiation) yield suboptimal results for advanced NB.
- Immune-based therapies offer a promising avenue for recurrent or advanced NB.
Discussion:
- Review of preclinical studies and early-phase clinical trials for cellular therapies in NB.
- Evaluation of various cellular approaches including natural killer (NK) cells, gammadelta T cells, chimeric antigen receptor (CAR) T cells, dendritic cells, and allogeneic hematopoietic stem cell transplantation (HSCT).
Key Insights:
- Cellular immunotherapies are being actively investigated for neuroblastoma treatment.
- Diverse cellular platforms demonstrate potential in preclinical and early clinical settings.
- These approaches aim to overcome limitations of traditional therapies for high-risk NB.
Outlook:
- Further clinical development of cellular therapies is warranted for neuroblastoma.
- Optimizing these immunotherapeutic strategies could improve outcomes for affected children.
- Integration of cellular therapies into NB treatment protocols may enhance efficacy.
